menu
    • menu

    Find Losartan Potassium manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 28
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 124750-99-8, Cozaar, Losartan potassium salt, Lorzaar, Losacar, Losaprex
    Molecular Formula
    C22H22ClKN6O
    Molecular Weight
    461.0  g/mol
    InChI Key
    OXCMYAYHXIHQOA-UHFFFAOYSA-N
    FDA UNII
    3ST302B24A
    Losartan Potassium
    An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
    1 2D Structure

    Losartan Potassium

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
    2.1.2 InChI
    InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
    2.1.3 InChI Key
    OXCMYAYHXIHQOA-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+]
    2.2 Other Identifiers
    2.2.1 UNII
    3ST302B24A
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-butyl-4-chloro-1-((2'-(1h-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-methanol

    2. Cozaar

    3. Dup 753

    4. Dup-753

    5. Dup753

    6. Losartan

    7. Losartan Monopotassium Salt

    8. Mk 954

    9. Mk-954

    10. Mk954

    11. Monopotassium Salt, Losartan

    12. Potassium, Losartan

    13. Salt, Losartan Monopotassium

    2.3.2 Depositor-Supplied Synonyms

    1. 124750-99-8

    2. Cozaar

    3. Losartan Potassium Salt

    4. Lorzaar

    5. Losacar

    6. Losaprex

    7. Hyzaar

    8. Dup 753

    9. Nu-lotan

    10. Mk 954

    11. Lortaan

    12. Losata

    13. Tancin

    14. Mk-0954

    15. Losartanpotassium

    16. Losartan Potassium (dup 753)

    17. Mk0954

    18. L-158086

    19. Losartan Monopotassium Salt

    20. 3st302b24a

    21. Aradois

    22. Zaart

    23. Dup-753

    24. Presartan-50

    25. E-3340

    26. 2-butyl-4-chloro-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol, Monopotassium Salt

    27. 124750-99-8 (ka+)

    28. Potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

    29. Lifezar

    30. Lorzaan

    31. Losacor

    32. Tenopres

    33. Lotim

    34. Niten

    35. Ocsaar

    36. Du Pont-753

    37. Neo Lotan

    38. 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Monopotassium Salt

    39. 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol, Monopotassium Salt

    40. Mfcd09850721

    41. Mk-954

    42. Du Pont 753

    43. Losartan Potassium [usan]

    44. Covance

    45. Unii-3st302b24a

    46. Losartan Potassium [usan:usp]

    47. Potassium 5-(4'-((2-butyl-4-chloro-5-(hydroxymethyl)-1h-imidazol-1-yl)methyl)biphenyl-2-yl)tetrazol-1-ide

    48. Cozaar (tn)

    49. Dup-753 Potassium

    50. Mk 0954

    51. Losartan Potassium,(s)

    52. Schembl42079

    53. Mls001401407

    54. Ex-89

    55. Dtxsid3044209

    56. Losartan Potassium [jan]

    57. Losartan Potassium (jp17/usp)

    58. Losartan Potassium [hsdb]

    59. Hms2051m12

    60. Hms2090o22

    61. Hms2235f20

    62. Hms3369f08

    63. Hms3393m12

    64. Losartan Potassium [vandf]

    65. Losartan Potassium [mart.]

    66. Act02618

    67. Bcp05332

    68. Bcp29397

    69. Losartan Potassium [usp-rs]

    70. Losartan Potassium [who-dd]

    71. Akos015955543

    72. Akos025310168

    73. Ac-1072

    74. Ccg-100869

    75. Losartan Potassium, Analytical Standard

    76. Nc00119

    77. 2-butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1h-imidazole-5-methanol Potassium

    78. Losartan Monopotassium Salt [mi]

    79. Losartan Potassium [orange Book]

    80. Losartan Potassium [ep Monograph]

    81. 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]imidazole-5-methanol Potassium Salt

    82. Bl164642

    83. Epo

    84. Hyzaar Component Losartan Potassium

    85. Losartan Potassium [usp Monograph]

    86. Smr000469593

    87. Ft-0625705

    88. L-185

    89. L0232

    90. Losartan Potassium Component Of Hyzaar

    91. D00357

    92. Ab01275507-01

    93. 750l998

    94. A805291

    95. Sr-05000001514

    96. Sr-05000001514-1

    97. Q27257991

    98. Losartan Potassium, European Pharmacopoeia (ep) Reference Standard

    99. Losartan Potassium Is Known As A Potent, Synthetic At1 Receptor Antagonist.

    100. Losartan Potassium, United States Pharmacopeia (usp) Reference Standard

    101. Losartan Potassium, Pharmaceutical Secondary Standard; Certified Reference Material

    102. [2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Potassium;losartan Potassium

    103. 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-, Monopotassium Salt

    104. Potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol.

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 461.0 g/mol
    Molecular Formula C22H22ClKN6O
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count8
    Exact Mass460.1180685 g/mol
    Monoisotopic Mass460.1180685 g/mol
    Topological Polar Surface Area77.7 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity526
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameCozaar
    PubMed HealthLosartan (By mouth)
    Drug ClassesCardiovascular Agent, Renal Protective Agent
    Drug LabelCOZAAR1(losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt.Its...
    Active IngredientLosartan potassium
    Dosage FormTablet
    RouteOral
    Strength100mg; 25mg; 50mg
    Market StatusPrescription
    CompanyMerck Sharp Dohme

    2 of 4  
    Drug NameLosartan potassium
    Drug LabelLosartan potassium tablets USP are an angiotensin II receptor (type AT1) antagonist. Losartan potassium, USP a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium...
    Active IngredientLosartan potassium
    Dosage FormTablet
    RouteOral
    Strength25mg; 100mg; 50mg
    Market StatusPrescription
    CompanyUpsher Smith; Teva; Apotex; Alembic Pharms; Aurobindo Pharma; Torrent Pharms; Lupin; Sandoz; Prinston; Roxane; Watson Labs; Macleods Pharms; Ipca Labs; Vivimed Labs; Micro Labs Ltd India; Cadista Pharms; Zydus Pharms Usa; Mylan

    3 of 4  
    Drug NameCozaar
    PubMed HealthLosartan (By mouth)
    Drug ClassesCardiovascular Agent, Renal Protective Agent
    Drug LabelCOZAAR1(losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt.Its...
    Active IngredientLosartan potassium
    Dosage FormTablet
    RouteOral
    Strength100mg; 25mg; 50mg
    Market StatusPrescription
    CompanyMerck Sharp Dohme

    4 of 4  
    Drug NameLosartan potassium
    Drug LabelLosartan potassium tablets USP are an angiotensin II receptor (type AT1) antagonist. Losartan potassium, USP a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium...
    Active IngredientLosartan potassium
    Dosage FormTablet
    RouteOral
    Strength25mg; 100mg; 50mg
    Market StatusPrescription
    CompanyUpsher Smith; Teva; Apotex; Alembic Pharms; Aurobindo Pharma; Torrent Pharms; Lupin; Sandoz; Prinston; Roxane; Watson Labs; Macleods Pharms; Ipca Labs; Vivimed Labs; Micro Labs Ltd India; Cadista Pharms; Zydus Pharms Usa; Mylan

    4.2 Drug Indication

    Indicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

    FDA Label

    Proteinuria, Treatment of heart failure, Treatment of hypertension

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Erythropoietin and epoetin alfa are involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is reported to increase the reticulocyte count within 10 days of initiation, followed by increases in the RBC count, hemoglobin, and hematocrit, usually within 2 to 6 weeks. Depending on the dose administered, the rate of hemoglobin increase may vary. In patients receiving hemodialysis, a greater biologic response is not observed at doses exceeding 300 Units/kg 3 times weekly. Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised. In anemic patients with chronic renal failure (CRF), administration with epoetin alfa stimulated erythropoiesis by increasing the reticulocyte count within 10 days, followed by increases in the red cell count, hemoglobin, and hematocrit, usually within 2 to 6 weeks. Epoetin alfa was shown to be effective in increasing hematocrit in zidovudine-treated HIV-infected patients and anemic cancer patients undergoing chemotherapy.

    5.2 MeSH Pharmacological Classification

    Angiotensin II Type 1 Receptor Blockers

    Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)

    Anti-Arrhythmia Agents

    Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Pharmacological Classes
    Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]
    5.4 ATC Code

    B - Blood and blood forming organs

    B03 - Antianemic preparations

    B03X - Other antianemic preparations

    B03XA - Other antianemic preparations

    B03XA01 - Erythropoietin

    5.5 Absorption, Distribution and Excretion

    Absorption

    The time to reach peak concentration is slower via the subcutaneous route than the intravenous route which ranges from 20 to 25 hours, and the peak is always well below the peak achieved using the intravenous route (510% of those seen with IV administration). The bioavailability of subcutaneous injectable erythropoietin is much lower than that of the intravenously administered product and is approximately 20-40%. **Adult and paediatric patients with CRF:** Following subcutaneous administration, the peak plasma levels are achieved within 5 to 24 hours. **Cancer patients receiving cyclic chemotherapy:** The average time to reach peak plasma concentration was approximately 13.3 12.4 hours after 150 Units/kg three times per week (TIW) subcutaneous (SC) dosing. The Cmax is expected be 3- to 7- fold higher and the Tmax is expected to be 2- to 3-fold longer in patients receiving a 40,000 Units SC weekly dosing regimen.

    Route of Elimination

    Erythropoietin and epoetin alfa are cleared via uptake and degradation via the EPO-R-expressing cells, and may also involve other cellular pathways in the interstitium, probably via cells in the reticuloendothelial scavenging pathway or lymphatic system. Only a small amount of unchanged epoetin alfa is found in the urine.

    Volume of Distribution

    In healthy volunteers, the volume of distribution of intravenous epoetin alfa was generally similar to the plasma volume (range of 4063.80 mL/kg), indicating limited extravascular distribution.

    Clearance

    **Healthy volunteers: *

    In male volunteers receiving intravenous epoetin alfa, the total body clearance was approximately 8.12 1.00 mL/h/kg. **Cancer patients receiving cyclic chemotherapy:*

    The average clearance was approximately 20.2 15.9 mL/h/kg after 150 Units/kg three times per week (TIW) subcutaneous (SC) dosing. The patients receiving a 40,000 Units SC weekly dosing regimen display a lower clearance (9.2 4.7 mL/h/kg).

    5.6 Metabolism/Metabolites

    Binding of erythropoietin and epoetin alfa to EPO-R leads to cellular internalization, which involves the degradation of the ligand. Erythropoietin and epoetin alfa may also be degraded by the reticuloendothelial scavenging pathway or lymphatic system.

    5.7 Biological Half-Life

    **Healthy volunteers:*

    The half life is approximately 4 hours in healthy volunteers receiving an intravenous injection. A half-life of approximately 6 hours has been reported in children. **Adult and paediatric patients with CRF:*

    The elimination half life following intravenous administration ranges from 4 to 13 hours, which is about 20% longer in CRF patients than that in healthy subjects. The half life is reported to be similar between adult patients receiving or not receiving dialysis. **Cancer patients receiving cyclic chemotherapy:*

    Following subcutaneous administration, the average half life is 40 hours with range of 16 to 67 hours.

    5.8 Mechanism of Action

    Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. The affinity (Kd) of EPO for its receptor on human cells is 100 to 200 pM. Upon binding to EPO-R on the surface of erythroid progenitor cells, a conformational change is induced which brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity. JAK2 molecules are subsequently activated via phosphorylation, then phosphorylate tyrosine residues in the cytoplasmic domain of the EPO-R that serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins. The signalling proteins include STAT5 that once phosphorylated by JAK2, dissociates from the EPO-R, dimerizes, and translocates to the nucleus where they serve as transcription factors to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. The inhibition of apoptosis by the EPO-activated JAK2/STAT5/Bcl-x pathway is critical in erythroid differentiation. Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphatidylinositol 3-kinase (PI3K), and phospholipase C-1.

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 100MG

    USFDA APPLICATION NUMBER - 20386

    read-more

    DOSAGE - TABLET;ORAL - 25MG

    USFDA APPLICATION NUMBER - 20386

    read-more

    DOSAGE - TABLET;ORAL - 50MG

    USFDA APPLICATION NUMBER - 20386

    read-more

    DOSAGE - TABLET;ORAL - 12.5MG;100MG

    USFDA APPLICATION NUMBER - 20387

    read-more

    DOSAGE - TABLET;ORAL - 12.5MG;50MG

    USFDA APPLICATION NUMBER - 20387

    read-more

    DOSAGE - TABLET;ORAL - 25MG;100MG

    USFDA APPLICATION NUMBER - 20387

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 124750-99-8 / Losartan Potassium API manufacturers, exporters & distributors?

    Losartan Potassium manufacturers, exporters & distributors 1

    34

    PharmaCompass offers a list of Losartan Potassium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Losartan Potassium manufacturer or Losartan Potassium supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Losartan Potassium manufacturer or Losartan Potassium supplier.

    PharmaCompass also assists you with knowing the Losartan Potassium API Price utilized in the formulation of products. Losartan Potassium API Price is not always fixed or binding as the Losartan Potassium Price is obtained through a variety of data sources. The Losartan Potassium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Losartan Potassium

    Synonyms

    124750-99-8, Cozaar, Losartan potassium salt, Lorzaar, Losacar, Losaprex

    Cas Number

    124750-99-8

    Unique Ingredient Identifier (UNII)

    3ST302B24A

    About Losartan Potassium

    An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

    Cozaar Manufacturers

    A Cozaar manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cozaar, including repackagers and relabelers. The FDA regulates Cozaar manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cozaar API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Cozaar manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Cozaar Suppliers

    A Cozaar supplier is an individual or a company that provides Cozaar active pharmaceutical ingredient (API) or Cozaar finished formulations upon request. The Cozaar suppliers may include Cozaar API manufacturers, exporters, distributors and traders.

    click here to find a list of Cozaar suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Cozaar USDMF

    A Cozaar DMF (Drug Master File) is a document detailing the whole manufacturing process of Cozaar active pharmaceutical ingredient (API) in detail. Different forms of Cozaar DMFs exist exist since differing nations have different regulations, such as Cozaar USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Cozaar DMF submitted to regulatory agencies in the US is known as a USDMF. Cozaar USDMF includes data on Cozaar's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cozaar USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Cozaar suppliers with USDMF on PharmaCompass.

    Cozaar JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Cozaar Drug Master File in Japan (Cozaar JDMF) empowers Cozaar API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Cozaar JDMF during the approval evaluation for pharmaceutical products. At the time of Cozaar JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Cozaar suppliers with JDMF on PharmaCompass.

    Cozaar KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Cozaar Drug Master File in Korea (Cozaar KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cozaar. The MFDS reviews the Cozaar KDMF as part of the drug registration process and uses the information provided in the Cozaar KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Cozaar KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cozaar API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Cozaar suppliers with KDMF on PharmaCompass.

    Cozaar CEP

    A Cozaar CEP of the European Pharmacopoeia monograph is often referred to as a Cozaar Certificate of Suitability (COS). The purpose of a Cozaar CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cozaar EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cozaar to their clients by showing that a Cozaar CEP has been issued for it. The manufacturer submits a Cozaar CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cozaar CEP holder for the record. Additionally, the data presented in the Cozaar CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cozaar DMF.

    A Cozaar CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cozaar CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Cozaar suppliers with CEP (COS) on PharmaCompass.

    Cozaar WC

    A Cozaar written confirmation (Cozaar WC) is an official document issued by a regulatory agency to a Cozaar manufacturer, verifying that the manufacturing facility of a Cozaar active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cozaar APIs or Cozaar finished pharmaceutical products to another nation, regulatory agencies frequently require a Cozaar WC (written confirmation) as part of the regulatory process.

    click here to find a list of Cozaar suppliers with Written Confirmation (WC) on PharmaCompass.

    Cozaar NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cozaar as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Cozaar API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Cozaar as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Cozaar and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cozaar NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Cozaar suppliers with NDC on PharmaCompass.

    Cozaar GMP

    Cozaar Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Cozaar GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cozaar GMP manufacturer or Cozaar GMP API supplier for your needs.

    Cozaar CoA

    A Cozaar CoA (Certificate of Analysis) is a formal document that attests to Cozaar's compliance with Cozaar specifications and serves as a tool for batch-level quality control.

    Cozaar CoA mostly includes findings from lab analyses of a specific batch. For each Cozaar CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Cozaar may be tested according to a variety of international standards, such as European Pharmacopoeia (Cozaar EP), Cozaar JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cozaar USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search